Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
ELPROINTL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Elpro International Ltd has acquired 95,454 equity shares of Natco Pharma Limited for a total cash consideration of INR 10.01 Crores. This is a fresh acquisition with no prior holding in Natco Pharma. The purpose is stated as investment, and the deal is not a related party transaction. Natco Pharma is a listed pharmaceutical company with a consolidated turnover of INR 4,784 Crores in FY 2024-25, operating in oncology and specialty medicines.
This is a small investment stake (around 0.013% of Natco Pharma) funded entirely from cash. Since this is outside Elpro's core line of business and involves a minor shareholding, the acquisition is unlikely to materially move Elpro's stock price or change its business direction. Investors should view it as a treasury/passthrough investment rather than a strategic move.